Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Nulojix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.
This Nulojix market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The key company operating in the nulojix market is Bristol-Myers Squibb. North America was the largest region in the nulojix market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nulojix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the nulojix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Market growth during the historic period can be attributed to the rising prevalence of chronic kidney disease, advancements in immunosuppressive therapies, increased demand for organ transplantation, favorable reimbursement policies, and growing healthcare expenditures. Growth during the market's forecast period can be linked to the rising emphasis on personalized medicine, the increasing incidence of autoimmune disorders, improvements in healthcare infrastructure, ongoing clinical trials, and greater investments in biopharmaceuticals.
Key trends expected during this period include progress in monoclonal antibody technology, innovations in immunotherapy, advancements in organ transplantation, the development of enhanced biological drugs, and continued research and development efforts. The increasing prevalence of chronic kidney disease is expected to drive the growth of the nulojix market in the future. Chronic kidney disease is a long-term condition where the kidneys progressively lose their ability to filter waste and maintain vital bodily functions, which can lead to serious health complications.
Factors such as aging populations, underlying health conditions, and limited early diagnosis are contributing to the rise in chronic kidney disease cases, thus increasing the demand for effective management and treatments. Nulojix, an immunosuppressive drug, is beneficial for patients by preventing organ rejection in kidney transplant recipients and reducing the risk of graft dysfunction, thereby improving long-term transplant outcomes and enhancing the overall quality of life for individuals managing chronic conditions requiring transplantation. According to a June 2023 report by Kidney Research UK, approximately 7.2 million people in the UK are living with chronic kidney disease, which represents over 10% of the population. Among these, 3.25 million are in the advanced stages, while 3.9 million are in the early stages. By 2033, the number of individuals affected is expected to rise to 7.61 million, thus driving the demand for treatments such as nulojix.
The growth in the number of organ transplant procedures is also expected to propel the nulojix market. Organ transplants involve replacing a damaged or failing organ with a healthy donor organ to restore normal function and improve the patient's quality of life. The rise in transplants is due to increased cases of organ failure, advancements in medical technology, and a growing donor pool, leading to a higher demand for effective transplant procedures and post-operative care.
Nulojix plays a crucial role in managing immune responses, reducing the risk of organ rejection, and ensuring the success of transplant procedures. For example, the United Network for Organ Sharing reported that in 2022, the U.S. saw a record 42,887 organ transplants, a 3.7% increase from the previous year, including record numbers for liver, heart, and lung transplants. The surge in organ transplant procedures is thus contributing to the growth of the nulojix market.
Rising healthcare expenditure is another key factor expected to drive the growth of the nulojix market. Healthcare spending covers medical care, hospital services, preventive care, medications, research, and infrastructure, all aimed at improving the health and well-being of individuals. Factors such as an aging population, advancements in medical technology, the increasing prevalence of chronic diseases, and the growing demand for healthcare services are contributing to the rise in healthcare spending.
Increased healthcare expenditure supports the use of nulojix by reducing the need for extended hospital stays and additional immunosuppressive therapies, ensuring efficient post-transplant care and improved patient outcomes. According to a report by the American Medical Association, U.S. health spending increased by 4.1% to $4.5 trillion in 2022, representing 17.3% of GDP. This rising healthcare expenditure is therefore driving the growth of the nulojix market.
Key Topics Covered:
1. Executive Summary
2. Nulojix Market Characteristics
3. Nulojix Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route of Administration (ROA)
3.3. Mechanism of Action (MOA)
3.4. Safety and Efficacy
4. Nulojix Market Trends and Strategies
5. Nulojix Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market
6. Global Nulojix Growth Analysis and Strategic Analysis Framework
6.1. Global Nulojix PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis of End Use Industries
6.3. Global Nulojix Market Growth Rate Analysis
6.4. Global Nulojix Historic Market Size and Growth, 2019-2024, Value ($ Million)
6.5. Global Nulojix Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Million)
6.6. Global Nulojix Total Addressable Market (TAM)
7. Global Nulojix Pricing Analysis & Forecasts
8. Nulojix Market Segmentation
8.1. Global Nulojix Market, Segmentation by Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
- Kidney Transplantation
- Autoimmune Diseases
- Organ Transplantation
8.2. Global Nulojix Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
8.3. Global Nulojix Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
- Hospitals
- Specialty Clinics
- Transplant Centers
9. Global Nulojix Epidemiology of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence and Prevalence of Clinical Indications
10. Nulojix Market Regional and Country Analysis
10.1. Global Nulojix Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10.2. Global Nulojix Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
For more information about this report visit https://www.researchandmarkets.com/r/h4eflc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
